July 30, 2008
Cutting Edge Information’s Research on Monoclonal Antibodies Drives Forecasts for the Oncology Market
By 2012, sales of monoclonal antibodies will represent nearly 50% of oncology drug sales, according to a new study by Cutting Edge Information.
Successful brands such as Rituxan, Herceptin and Erbitux are all expected to grow by anywhere from 23% to 80% by 2013. Furthermore, there are several monoclonal antibodies, such as Amgen's Denosumab and Bristol-Myers Squibb's ipilumumab, in development poised to experience similar growth after they launch.
"In this era where blockbuster drugs are few and far between, the cancer market is one area that is poised for tremendous growth," said Eric Bolesh, research team leader at Cutting Edge Information. "The amount of research dollars that the pharma industry is spending on oncology drug development is sure to deliver new market leaders in the next five years."
Monoclonal antibodies' (MAbs) efficacy and diminished side effects make them an attractive choice for oncologists. In 2007, MAb sales leapt by $3 billion over 2006 levels to almost $14 billion. This increase comes thanks to the three highest-selling MAbs -- Herceptin, Rituxan and Avastin, which combined for more than $12.4 billion in 2007 after 2006 sales of $9.7 billion.
MAb sales will continue to grow by a steady $2 billion to $3 billion per year. Herceptin, Rituxan, Avastin and Erbitux will maintain market dominance with nearly $25 billion in sales by 2012, or 89% of the MAb market. In addition, six new MAbs are slotted for launch in the next two years.
The 420+ page study examines 17 monoclonal antibodies and more than 120 other drugs, and provides the following market analysis:
-- Individual Drug Profiles - Drug profiles include information about drugs' competitive, strategic and market growth positions. -- Oncology Indication Market Outlook - Detailed outlooks for the breast, colorectal, lung and prostate cancer and leukemia markets. -- Company Profiles - Oncology breakdowns for companies that either have established oncology franchises or exciting development pipelines for new cancer compounds.
CONTACT INFORMATION: Eric Bolesh Email Contact 919-433-0209
SOURCE: Cutting Edge Information